View ValuationSurgical Science Sweden 향후 성장Future 기준 점검 3/6Surgical Science Sweden (는) 각각 연간 28.8% 및 10.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 28.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 4.2% 로 예상됩니다.핵심 정보28.8%이익 성장률28.84%EPS 성장률Medical Equipment 이익 성장17.1%매출 성장률10.3%향후 자기자본이익률4.16%애널리스트 커버리지Low마지막 업데이트24 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Oct 01Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026.공고 • Sep 04+ 3 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2026 Results on Aug 19, 2026Surgical Science Sweden AB (publ) announced that they will report first half, 2026 results on Aug 19, 2026공고 • May 16Surgical Science Sweden AB (Publ) Appoints Gisli Hennermark as New Chairman of the Board of DirectorsSurgical Science Sweden AB (publ) announced at its AGM held on May 15, 2025, the shareholders approved Gisli Hennermark was elected new Chairman of the Board of Directors.공고 • Feb 04Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025. Location: gothenburg Sweden공고 • Dec 20Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million.Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million on December 19, 2024. A cash consideration valued at £0.13 per share will be paid by Surgical Science Sweden AB (publ) on a cash and debt free basis. The consideration necessary to satisfy the Acquisition in full will be funded from Surgical Science's existing cash resources. Surgical Science drew down £17 million under the DB Facility prior to the date of this announcement and intends to settle the consideration payable pursuant to the Acquisition out of the cash on its balance sheet, including the funds drawn down under the DB Facility. Strand Hanson, joint financial adviser to Surgical Science, confirms that it is satisfied that sufficient resources are available to Surgical Science to satisfy in full the cash consideration payable to Intelligent Ultrasound Shareholders under the terms of the Acquisition. Surgical Science does not intend to make any material changes to the balance of skills and functions of the employees and management of Intelligent Ultrasound. Surgical Science will fully safeguard the existing employment rights, including pension rights, of Intelligent Ultrasound's employees. The Intelligent Ultrasound Directors intend to recommend unanimously that Intelligent Ultrasound Shareholders vote in favour of the Scheme at the Court Meeting and vote in favour of the Resolution to be proposed at the General Meeting as the Intelligent Ultrasound Directors. It is intended that the Acquisition will be implemented by way of a Court-sanctioned Scheme of Arrangement. The Intelligent Ultrasound Directors, who have been so advised by Cavendish as to the financial terms of the Acquisition, consider the terms of the Acquisition to be fair and reasonable. The approval of the Scheme by a majority in number of the Intelligent Ultrasound Shareholders who are present and vote (and are entitled to vote), whether in person or by proxy, at the Court Meeting and who represent 75% or more in value of the Scheme Shares voted by such Intelligent Ultrasound Shareholders, he Resolution required to approve and implement the Scheme being duly passed by Intelligent Ultrasound Shareholders representing the requisite majority or majorities of the votes cast at the General Meeting and third party clearance. It is intended that the London Stock Exchange will be requested to cancel admission of the Intelligent Ultrasound Shares to trading on AIM to become effectiveas soon as practicable after the Effective Date. The Scheme is expected to become effective in the first quarter of 2025, provided all the conditions are satisfied. Pareto Securities AB, Strand Hanson Limited, Baker McKenzie LLP acted as advisor to Surgical Science, Cavendish Capital Markets RBG Legal Services Limited, trading as Memery Crystal, is acting as advisers to Intelligent Ultrasound.공고 • Oct 29+ 2 more updatesSurgical Science Sweden AB (publ) to Report Nine Months, 2025 Results on Nov 13, 2025Surgical Science Sweden AB (publ) announced that they will report nine months, 2025 results on Nov 13, 2025공고 • Oct 22Surgical Science Sweden AB (publ) Appoints Nomination Committee for the 2025 Annual General MeetingSurgical Science Sweden AB (publ) appointed following members to the nomination Committee for the 2025 Annual General Meeting: Åsa Hedin, appointed by Marknads potential AB Anna Sundberg, appointed by Handelsbanken Fonder, Erik Sprinchorn, appointed by TIN Fonder, Roland Bengtsson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company’s Nomination Committee established at the Annual General Meeting of Surgical Science on May 16, 2024. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just below 27 percent of all shares in the company as of August 31, 2024. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding: (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee, (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.공고 • Jul 01Surgical Science Sweden AB (publ) Appoints Tom Englund as New CEO, Effective October 1, 2024Surgical Science Sweden AB (publ) announced that Tom Englund will take over as the new CEO of Surgical Science on October 1, 2024. Tom currently works as COO and Deputy CEO at Instabee. He will succeed the current CEO Gisli Hennermark, who after October 1 will remain in an advisory role until the end of March 2025. Tom Englund holds a Master of Science in Industrial Engineering and Management from Linköping University. Previous experiences include Accenture and Roland Berger, various roles within Atlas Copco where Tom spent seven years based in Stockholm and Shanghai, and Tobii where he worked for twelve years. At Tobii, a leading company in eye tracking, revenues during Tom's tenure grew from around SEK 200 million to SEK 1.4 billion. Tom was CEO of the Tobii Pro business unit and later also Deputy CEO of the Tobii Group. Since 2021, Tom has worked for Instabox, whichthrough a merger with Budbee in 2022 became Instabee. Tom is the COO and Deputy CEO at Instabee. From his roles, Tom has experience in leading fast-growing high-tech organizations with a focus on profitable growth, developing business models, acquiring and integrating businesses, and scaling and merging organizations in a complex structure and international environment. Tom will start his employment in Surgical Science on August 19 and will assume the position of CEO on October 1, 2024. Tom has no board assignments except for internal assignments within the Instabee Group.공고 • Mar 12Gisli Hennermark Intends to Leave as CEO of Surgical Science Sweden AB (Publ)Surgical Science Sweden AB (publ) announced that Gisli Hennermark, CEO has informed the board that he intends to leave his position. The board now initiates the work of finding a successor to Gisli. That process will be led by the chairman of the board, Roland Bengtsson. Gisli remains as CEO until the board appoints a new CEO and will be an advisor to the new CEO until March, 2025.공고 • Nov 10+ 2 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2024 Results on Aug 22, 2024Surgical Science Sweden AB (publ) announced that they will report first half, 2024 results on Aug 22, 2024공고 • Oct 26Surgical Science Sweden AB (publ) Announces Appointments to its Nomination CommitteeSurgical Science Sweden AB (publ) announced that the following were appointed to it's Nomination Committee for the 2024 Annual General Meeting: Åsa Hedin, appointed by Marknadspotential AB; Celia Grip, appointed by Swedbank Robur Fonder; Anna Sundberg, appointed by Handelsbanken Fonder; Roland Bengtsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company's Nomination Committee established at the Annual General Meeting of Surgical Science on May 6, 2020. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just above 27% of all shares in the company as of September 30, 2023. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable), (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.공고 • Oct 24Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024. Agenda: To consider the election of board members; to consider the election of Chairman of the Board; to consider the resolution on board remuneration with the division between the chairman and other members of the board; to consider the resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable); to consider the election of auditors; to consider the resolution on remuneration of auditors; and to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.공고 • Aug 27Surgical Science Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 21, 2024Surgical Science Sweden AB (publ) announced that they will report fiscal year 2023 results on Feb 21, 2024공고 • May 18Surgical Science Sweden AB (publ) Approves Election of Åsa Bredin as Board MemberSurgical Science Sweden AB (publ) at its Annual General Meeting held on May 17, 2023, approved new election of Åsa Bredin as Board member.이익 및 매출 성장 예측OTCPK:SUSR.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,230168175215412/31/20271,104135134169412/31/20269889413314243/31/20269775293150N/A12/31/2025992673080N/A9/30/2025975701764N/A6/30/2025943924290N/A3/31/202594714156104N/A12/31/202488413290137N/A9/30/202486019373120N/A6/30/2024838198100151N/A3/31/2024842208159206N/A12/31/2023883234194238N/A9/30/2023906253231277N/A6/30/2023901234194234N/A3/31/2023872221140179N/A12/31/202280318895129N/A9/30/20227501381138N/A6/30/20226401246180N/A3/31/20224891014559N/A12/31/2021367862539N/A9/30/2021209305969N/A6/30/2021138211726N/A3/31/2021122181120N/A12/31/2020105161523N/A9/30/202010414414N/A6/30/2020112194254N/A3/31/2020107173747N/A12/31/201910213N/A55N/A9/30/2019886N/A56N/A6/30/201970-5N/A12N/A3/31/201968-5N/A9N/A12/31/201866-5N/A7N/A9/30/201860-3N/A9N/A6/30/201857-6N/A0N/A3/31/201856-7N/A8N/A12/31/201757-3N/A7N/A9/30/2017654N/A6N/A6/30/2017603N/A12N/A3/31/2017594N/A11N/A12/31/2016583N/A13N/A12/31/2015522N/A8N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SUSR.F 의 연간 예상 수익 증가율(28.8%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: SUSR.F 의 연간 수익(28.8%)이 US 시장(17.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SUSR.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: SUSR.F 의 수익(연간 10.3%)이 US 시장(연간 12.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SUSR.F 의 수익(연간 10.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SUSR.F의 자본 수익률은 3년 후 4.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/24 09:50종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Surgical Science Sweden AB (publ)는 6명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Simon JonssonBerenbergSimon LarssonDanske BankKristofer Liljeberg-SvenssonDNB Carnegie3명의 분석가 더 보기
공고 • Oct 01Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026.
공고 • Sep 04+ 3 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2026 Results on Aug 19, 2026Surgical Science Sweden AB (publ) announced that they will report first half, 2026 results on Aug 19, 2026
공고 • May 16Surgical Science Sweden AB (Publ) Appoints Gisli Hennermark as New Chairman of the Board of DirectorsSurgical Science Sweden AB (publ) announced at its AGM held on May 15, 2025, the shareholders approved Gisli Hennermark was elected new Chairman of the Board of Directors.
공고 • Feb 04Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025. Location: gothenburg Sweden
공고 • Dec 20Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million.Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million on December 19, 2024. A cash consideration valued at £0.13 per share will be paid by Surgical Science Sweden AB (publ) on a cash and debt free basis. The consideration necessary to satisfy the Acquisition in full will be funded from Surgical Science's existing cash resources. Surgical Science drew down £17 million under the DB Facility prior to the date of this announcement and intends to settle the consideration payable pursuant to the Acquisition out of the cash on its balance sheet, including the funds drawn down under the DB Facility. Strand Hanson, joint financial adviser to Surgical Science, confirms that it is satisfied that sufficient resources are available to Surgical Science to satisfy in full the cash consideration payable to Intelligent Ultrasound Shareholders under the terms of the Acquisition. Surgical Science does not intend to make any material changes to the balance of skills and functions of the employees and management of Intelligent Ultrasound. Surgical Science will fully safeguard the existing employment rights, including pension rights, of Intelligent Ultrasound's employees. The Intelligent Ultrasound Directors intend to recommend unanimously that Intelligent Ultrasound Shareholders vote in favour of the Scheme at the Court Meeting and vote in favour of the Resolution to be proposed at the General Meeting as the Intelligent Ultrasound Directors. It is intended that the Acquisition will be implemented by way of a Court-sanctioned Scheme of Arrangement. The Intelligent Ultrasound Directors, who have been so advised by Cavendish as to the financial terms of the Acquisition, consider the terms of the Acquisition to be fair and reasonable. The approval of the Scheme by a majority in number of the Intelligent Ultrasound Shareholders who are present and vote (and are entitled to vote), whether in person or by proxy, at the Court Meeting and who represent 75% or more in value of the Scheme Shares voted by such Intelligent Ultrasound Shareholders, he Resolution required to approve and implement the Scheme being duly passed by Intelligent Ultrasound Shareholders representing the requisite majority or majorities of the votes cast at the General Meeting and third party clearance. It is intended that the London Stock Exchange will be requested to cancel admission of the Intelligent Ultrasound Shares to trading on AIM to become effectiveas soon as practicable after the Effective Date. The Scheme is expected to become effective in the first quarter of 2025, provided all the conditions are satisfied. Pareto Securities AB, Strand Hanson Limited, Baker McKenzie LLP acted as advisor to Surgical Science, Cavendish Capital Markets RBG Legal Services Limited, trading as Memery Crystal, is acting as advisers to Intelligent Ultrasound.
공고 • Oct 29+ 2 more updatesSurgical Science Sweden AB (publ) to Report Nine Months, 2025 Results on Nov 13, 2025Surgical Science Sweden AB (publ) announced that they will report nine months, 2025 results on Nov 13, 2025
공고 • Oct 22Surgical Science Sweden AB (publ) Appoints Nomination Committee for the 2025 Annual General MeetingSurgical Science Sweden AB (publ) appointed following members to the nomination Committee for the 2025 Annual General Meeting: Åsa Hedin, appointed by Marknads potential AB Anna Sundberg, appointed by Handelsbanken Fonder, Erik Sprinchorn, appointed by TIN Fonder, Roland Bengtsson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company’s Nomination Committee established at the Annual General Meeting of Surgical Science on May 16, 2024. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just below 27 percent of all shares in the company as of August 31, 2024. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding: (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee, (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.
공고 • Jul 01Surgical Science Sweden AB (publ) Appoints Tom Englund as New CEO, Effective October 1, 2024Surgical Science Sweden AB (publ) announced that Tom Englund will take over as the new CEO of Surgical Science on October 1, 2024. Tom currently works as COO and Deputy CEO at Instabee. He will succeed the current CEO Gisli Hennermark, who after October 1 will remain in an advisory role until the end of March 2025. Tom Englund holds a Master of Science in Industrial Engineering and Management from Linköping University. Previous experiences include Accenture and Roland Berger, various roles within Atlas Copco where Tom spent seven years based in Stockholm and Shanghai, and Tobii where he worked for twelve years. At Tobii, a leading company in eye tracking, revenues during Tom's tenure grew from around SEK 200 million to SEK 1.4 billion. Tom was CEO of the Tobii Pro business unit and later also Deputy CEO of the Tobii Group. Since 2021, Tom has worked for Instabox, whichthrough a merger with Budbee in 2022 became Instabee. Tom is the COO and Deputy CEO at Instabee. From his roles, Tom has experience in leading fast-growing high-tech organizations with a focus on profitable growth, developing business models, acquiring and integrating businesses, and scaling and merging organizations in a complex structure and international environment. Tom will start his employment in Surgical Science on August 19 and will assume the position of CEO on October 1, 2024. Tom has no board assignments except for internal assignments within the Instabee Group.
공고 • Mar 12Gisli Hennermark Intends to Leave as CEO of Surgical Science Sweden AB (Publ)Surgical Science Sweden AB (publ) announced that Gisli Hennermark, CEO has informed the board that he intends to leave his position. The board now initiates the work of finding a successor to Gisli. That process will be led by the chairman of the board, Roland Bengtsson. Gisli remains as CEO until the board appoints a new CEO and will be an advisor to the new CEO until March, 2025.
공고 • Nov 10+ 2 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2024 Results on Aug 22, 2024Surgical Science Sweden AB (publ) announced that they will report first half, 2024 results on Aug 22, 2024
공고 • Oct 26Surgical Science Sweden AB (publ) Announces Appointments to its Nomination CommitteeSurgical Science Sweden AB (publ) announced that the following were appointed to it's Nomination Committee for the 2024 Annual General Meeting: Åsa Hedin, appointed by Marknadspotential AB; Celia Grip, appointed by Swedbank Robur Fonder; Anna Sundberg, appointed by Handelsbanken Fonder; Roland Bengtsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company's Nomination Committee established at the Annual General Meeting of Surgical Science on May 6, 2020. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just above 27% of all shares in the company as of September 30, 2023. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable), (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.
공고 • Oct 24Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024. Agenda: To consider the election of board members; to consider the election of Chairman of the Board; to consider the resolution on board remuneration with the division between the chairman and other members of the board; to consider the resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable); to consider the election of auditors; to consider the resolution on remuneration of auditors; and to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.
공고 • Aug 27Surgical Science Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 21, 2024Surgical Science Sweden AB (publ) announced that they will report fiscal year 2023 results on Feb 21, 2024
공고 • May 18Surgical Science Sweden AB (publ) Approves Election of Åsa Bredin as Board MemberSurgical Science Sweden AB (publ) at its Annual General Meeting held on May 17, 2023, approved new election of Åsa Bredin as Board member.